Gyre Therapeutics Inc
GYRE7.690USD
+0.150+1.99%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
698.43MCap. mercado
167.69P/E TTM
Más Datos de Gyre Therapeutics Inc Compañía
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
Información de la empresa
Símbolo de cotizaciónGYRE
Nombre de la empresaGyre Therapeutics Inc
Fecha de salida a bolsaApr 12, 2006
Director ejecutivoMr. Ping Zhang
Número de empleados574
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 12
Dirección12770 High Bluff Drive, Suite 150
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92130
Teléfono16199493681
Sitio Webhttps://www.gyretx.com/
Símbolo de cotizaciónGYRE
Fecha de salida a bolsaApr 12, 2006
Director ejecutivoMr. Ping Zhang
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board, Interim Chief Executive Officer
Executive Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dan Weng
Dr. Dan Weng
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GNI Group Ltd
80.12%
Luo (Ying)
3.13%
Ma (Songjiang)
3.12%
The Vanguard Group, Inc.
1.27%
BlackRock Institutional Trust Company, N.A.
0.84%
Otro
11.52%
Accionistas
Accionistas
Proporción
GNI Group Ltd
80.12%
Luo (Ying)
3.13%
Ma (Songjiang)
3.12%
The Vanguard Group, Inc.
1.27%
BlackRock Institutional Trust Company, N.A.
0.84%
Otro
11.52%
Tipos de accionistas
Accionistas
Proporción
Corporation
80.12%
Individual Investor
7.04%
Investment Advisor
2.47%
Investment Advisor/Hedge Fund
0.91%
Research Firm
0.31%
Pension Fund
0.06%
Bank and Trust
0.02%
Hedge Fund
0.02%
Otro
9.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
124
82.04M
93.13%
+8.95M
2025Q1
126
82.96M
94.19%
+9.94M
2024Q4
117
71.62M
76.58%
-277.10K
2024Q3
117
71.44M
76.41%
-69.01K
2024Q2
108
71.18M
81.40%
+2.80M
2024Q1
95
70.73M
80.87%
+2.43M
2023Q4
101
67.57M
93.09%
+2.43M
2023Q3
124
846.01K
34.20%
-1.22M
2023Q2
137
853.88K
34.77%
-909.13K
2023Q1
173
927.40K
37.69%
-976.07K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GNI Group Ltd
72.77M
82.6%
+8.77M
+13.70%
Mar 12, 2025
Luo (Ying)
2.84M
3.22%
--
--
Sep 06, 2024
Ma (Songjiang)
2.84M
3.22%
-107.21K
-3.64%
Mar 12, 2025
The Vanguard Group, Inc.
1.10M
1.24%
+774.02K
+240.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
506.93K
0.58%
+12.53K
+2.53%
Mar 31, 2025
Ye (Weiguo)
700.00K
0.79%
+50.00K
+7.69%
Apr 01, 2025
Geode Capital Management, L.L.C.
312.32K
0.35%
+8.22K
+2.70%
Mar 31, 2025
SBI Securities Co., Ltd.
123.63K
0.14%
+22.39K
+22.12%
Mar 31, 2025
State Street Global Advisors (US)
128.77K
0.15%
+2.13K
+1.68%
Mar 31, 2025
Northern Trust Investments, Inc.
106.90K
0.12%
+3.52K
+3.40%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Fecha
Tipo
Relación
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
